Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sorivudine (BV-araU) 是口服有效的,嘧啶核苷抗代谢药物。它的抗病毒活性来自某些 DNA 病毒中存在的特定胸苷激酶选择性转化为核苷酸,从而反过来会干扰病毒 DNA 合成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 457 | 现货 | ||
5 mg | ¥ 1,090 | 现货 | ||
10 mg | ¥ 1,630 | 现货 | ||
25 mg | ¥ 2,780 | 现货 | ||
50 mg | ¥ 3,970 | 现货 |
产品描述 | Sorivudine (BV-araU) has antiviral activity against several viruses including varicella zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus by interfering with viral DNA synthesis. |
体外活性 | Sorivudine inhibits strains of HSV-1 and HSV-2 (ID50s (50% inhibitory dose): 0.39 and 0.67 μM, respectively). Sorivudine has antiviral activity against several viruses including varicella-zoster virus, herpes simplex type 1 virus, and Epstein-Barr virus. Sorivudine has in vitro inhibitory activity against the varicella-zoster virus at concentrations of 00001-0.004 mg/ml. These concentrations are over 1000-fold lower than those which are required for the inhibition of VZV replication by acyclovir 3 Sorivudine also inhibits HSV-I replication at concentrations ranging from 0.03-0.1 mg/ml [1][2]. |
体内活性 | Sorivudine has been evaluated in the treatment of HSV-l encephalitis when administered orally to mice. The survival of treated mice is prolonged at dosages in excess of 12.5 mg/kg. A significant decrease in mortality was achieved as well with doses in excess of 50 mg/kg. Sorivudine therapy at dosages as low as 20 mg/kg per day given intramuscularly or 100 mg/kg per day administered orally completely protected against viremia and mortality. There was no evidence of neurotoxicity or abnormalities in hematology or clinical chemistries. Doses as low as 0.2 mg/kg per day were effective; however, breakthrough viremia was noted at lower dosages [2]. |
别名 | BV-araU, 索立夫定 |
分子量 | 349.13 |
分子式 | C11H13BrN2O6 |
CAS No. | 77181-69-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (358.03 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8643 mL | 14.3213 mL | 28.6426 mL | 71.6066 mL |
5 mM | 0.5729 mL | 2.8643 mL | 5.7285 mL | 14.3213 mL | |
10 mM | 0.2864 mL | 1.4321 mL | 2.8643 mL | 7.1607 mL | |
20 mM | 0.1432 mL | 0.7161 mL | 1.4321 mL | 3.5803 mL | |
50 mM | 0.0573 mL | 0.2864 mL | 0.5729 mL | 1.4321 mL | |
100 mM | 0.0286 mL | 0.1432 mL | 0.2864 mL | 0.7161 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sorivudine 77181-69-2 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis nucleoside antiviral inhibit antimetabolite Epstein-Barr pyrimidine virus zoster oral varicella Inhibitor BV-araU herpes simplex 索立夫定 type inhibitor